Phase 2 N=48 Stellate Ganglion Block for COVID-induced Parosmia
COVID-19-Induced Parosmia
Primary: Parosmia Olfactory Dysfunction Outcomes Rating — 9; 9; 14; 11 score on a scale 0-112
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=139 COVID-19 Anosmia Study
Anosmia · Covid19
Primary: Change in Brief Smell Identification Test (BSIT) — 6.77; 7.20; 7.89; 7.88 score on a scale
Phase 2 N=20 Stellate Ganglion Block for COVID-19-Induced Olfactory Dysfunction
Anosmia · Hyposmia · Parosmia
Primary: Clinical Global Impression - Improvement (CGI-I) Score — 12; 8; 0; 0 Participants
Phase 2 N=51 Smell in Covid-19 and Efficacy of Nasal Theophylline
Covid19 · Anosmia · Olfactory Disorder
Primary: UPSIT — 59; 43 percentage of participants
N/A N=30 Acupuncture Therapy for COVID-Related Olfactory Loss
Olfactory Dysfunction · COVID-19
Primary: Change in University of Pennsylvania Smell Identification Test (UPSIT) Scores — 2.571; 3.182 score on a scale
Phase 2 N=68 Efficacy of Gabapentin for Post-Covid-19 Olfactory Dysfunction
COVID-19 · Olfactory Disorder · Anosmia
Primary: Clinical Global Impression of Improvement Scale (CGI-I) — 8; 20; 7; 12 Participants
N/A N=1,320 Validation of a Rapid Quantitative Test for Loss of Smell in COVID-19 Subjects
COVID-19
Primary: Sensitivity, Specificity and Accuracy — 889; 106; 27; 20 Participants
Phase 2 N=77 Smell in COVID-19 and Efficacy of Nasal Theophylline (SCENT 3)
COVID-19
Primary: Clinical Global Impression - Improvement Scale — 9; 9 Participants
N/A N=51 Steroid Nasal Irrigation for Flavor Evaluation and Detection Study
Olfactory Disorder
Primary: Pre- and Post-intervention Difference in Functional Connectivity Before and After Smell Training. — 5 Regions of interest
N/A N=100 Smell Sensitivity in Chronic Migraine: A Case-Control Study
Chronic Migraine · Olfactory Acuity
Primary: Comparison of UPSIT Scores Between Subjects and Controls at Two Time Points — 34.5; 35.9; 34.7; 36.1 UPSIT Score
Phase 2 N=27 Smell Changes & Efficacy of Nasal Theophylline
Olfactory Disorder · Anosmia · Viral Infection
Primary: Number of Patients With Improvement in Global Rating of Smell Change — 4; 3 Participants
Phase 3 N=22 Effects of Sodium Pyruvate Nasal Spray in COVID-19 Long Haulers.
Long COVID
Primary: Change in the Symptoms of Long COVID-19 Patients — 20.33; 27; 15.71; 22.43 units on a scale — p=0.200
N/A N=44 Swallowing Impairment After COVID-19 Infection
Covid19
Primary: Number of Participants With Impaired Swallowing Safety — 3; 1 Participants — p=<0.001
Phase 2 N=12 NeuroCovid Rehab and Recovery Related to COVID-19 Diagnosis
Coronavirus · Covid19
Primary: Change in Score of Patient Health Questionnaire-9 — -8.7; -5.5 score on a scale
Phase 3 N=30 Sodium Pyruvate Nasal Spray Treatment of COVID-19 Infection
COVID-19
Primary: Evaluate the Ability of Inhaled Nasal Sodium Pyruvate to Change COVID-19 Viral Titers. — 5.61; 6.57; 4.67; 5.86 Log10 viral RNA copies — p=0.0197
N/A N=125 Microbial Basis of Systemic Malodor and "People Allergic To Me" Conditions
Nutritional and Metabolic Diseases
Primary: Gut Microbiome — 52; 64; 25; 33 Normalized OTU counts
N/A N=28 Balance Function in Patients Post Corona Virus Disease 2019 (COVID-19)
Covid19
Primary: Motor Balance as Measured by Timed Up and Go (TUG) — 20.57 seconds
Phase 4 N=121 Olfactory Deficits and Donepezil Treatment in Cognitively Impaired Elderly
Alzheimer Disease · Mild Cognitive Impairment · Delirium, Dementia, Amnestic, Cognitive Disorders
Primary: Change Over Time in Selective Reminding Test (SRT) Scores — 36.14; 21.19; 39.99; 24.10 Words
N/A N=50 Evaluation of Smell and Taste in Fibromyalgia
Fibromyalgia
Primary: Sniffin' Sticks Test Score — 25.96; 36.40 score on a scale
N/A N=40 Effect of Chemotherapy With Paclitaxel/Cisplatin on Development Dysgeusia in Non Small Cell Lung Cancer
Non-Small Cell Lung Cancer · Dysgeusia · Taste Disorders
Primary: Dysgeusia (UMAMI Perception) — .3; .3 μmol/ml — p=0.013
Phase 1 N=35 A Study to Determine the Tolerability of Intranasal LMN-301
COVID-19
Primary: Number of Participants With Adverse Events — 5; 9; 10; 8 Participants
Phase 2 N=15 Directed Topical Drug Delivery for Treatment for PASC Hyposmia
Post Acute Sequelae Covid-19 Hyposmia
Primary: Percentage of Participants Achieving MCID (Minimal Clinically Important Difference) on the Smell Identification Test (SIT) — 66.70; 28.57; 66.70; 42.86 percentage of…
Phase 2 N=20 Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients
COVID-19
Primary: Number of Participants With Early Viral Clearance — 5; 4; 1; 0 Participants
Phase 4 N=41 Olfactory Deficits in MCI as Predictor of Improved Cognition on Donepezil
Mild Cognitive Impairment
Primary: Selective Reminding Test (SRT) — 33.61; 36.23; 36.81; 37.13 Words
N/A N=9 Smell, Voice and Nasal Swabs as Markers for Neuro-degenerative Disorders
Alzheimer Disease · Neurodegenerative Diseases
Primary: Alpha-synuclein Levels From Nasal Swabs
Early Phase 1 N=6 Intranasal Heparin Tolerability Study
Covid19
Primary: Number of Participants With Normal or Abnormal Activated Partial Thromboplastin Time (aPTT), Acute Phase Day 1 — 6; 0 Participants
N/A N=270 The Impact of the COVID-19 (SARS-CoV-2 Disease) on Psychopathology
Psychosis;Schizophrenic · Personality Disorders · Mood Disorders
Primary: Brief Psychiatric Rating Scale (BPRS) — 29.30; 32.80; 30.25 score on a scale
Phase 2 N=7 Helping Olfaction and Nutrition On Renal Replacement
End Stage Renal Disease · Olfactory Disorders
Primary: Change From Baseline in Smell Identification Test Score at 6 Weeks — 4 units on a scale
N/A N=16 Evaluation of Potential Screening Tools for Metabolic Body Odor and Halitosis
Nutritional and Metabolic Diseases
Primary: Number of Test Results Outside the Normal Range — 6; 3; 0; 0 participants
N/A N=64 Cognitive Rehabilitation in Post-COVID-19 Syndrome
Post-COVID-19 Syndrome
Primary: Recruitment Rate — 65 Participants